Enthüllung geglückt: Die Hauptbestandteile des historisch wichtigen Pharmakons Salvarsan (Arsphenamin, Ehrlich 606) konnten nun mithilfe der ESI‐Massenspektrometrie identifiziert werden: Es handelt sich um Cyclopolyarsane [RAs]n (siehe Struktur; n=3–6, R=3‐Amino‐4‐hydroxyphenyl).
Electron paramagnetic resonance (EPR) and X-ray photoelectron spectroscopy (XPS) have been employed to
investigate the nature of chromium-promoted tin(IV) oxide catalyst materials prepared via three routes, by
the impregnation of SnO2 using aqueous CrO3 or chromium(III) nitrate solutions and by coprecipitation from
aqueous solutions containing both Sn(IV) and Cr(III) ions. The catalyst materials exhibit three different
chromium signals (δ, γ, and β) in the EPR, depending on the treatment history of the catalysts. The δ-signal
results from dispersed Cr3+ ions and appears in the spectra of the Cr(III)-promoted SnO2 catalyst at all
temperatures and also in the spectra for the Cr(VI)-promoted catalyst after calcination. The β-signal detected
for the uncalcined Cr(III)-promoted catalyst obtained by coprecipitation is most probably due to the hydrated
γ-CrOOH phase but to Cr2O3 at higher calcination temperatures. Both Cr(III)- and Cr(VI)-promoted catalyst
materials exhibit the γ-signal after calcination at temperatures of ≥573K attributed to mixed-valence trimers
of the type “Cr(VI)−O−Cr(III)−O−Cr(VI)”, possibly indicating formation of the mixed-valence chromium
oxide Cr5O12. Photoreduction of Cr6+ to Cr5+ by the X-ray flux occurs during collection of Cr 2p XPS data
for Cr6+ compounds. XPS for Cr(VI)-promoted tin(IV) oxide catalysts dried at 333 K are consistent with
surface-adsorbed Cr6+ species (monochromate, dichromate). Cr6+ is still present after calcination at 573 K
together with Cr3+, corroborating the formation of the mixed-valence chromium phase Cr5O12. For the material
calcined at 673 K, the spectra indicate the presence of some Cr5O12 together with amorphous Cr2O3. Cr 2p
XPS spectra for both Cr(III)-promoted catalyst materials dried at 333 K exhibit peaks corresponding to Cr3+
most probably as γ-CrOOH. However, after calcination at 573 K, both types of material exhibit spectra
consistent with the formation of some Cr6+, consistent with the presence of the mixed-valence oxide Cr5O12.
For all three types of catalyst, Cr2O3 is the sole chromium oxide species present after calcination at calcination
temperatures.
The chemical transformations occurring during the thermal activation of chromiumpromoted tin(IV) oxide catalysts have been investigated by vibrational spectroscopy (FT-IR and FT-Raman), powder X-ray diffraction, transmission electron microscopy, and extended X-ray absorption fine structure and near-edge structure. Three methods of catalyst preparation have been employed: impregnation of SnO 2 using aqueous CrO 3 solutions, impregnation of SnO 2 using aqueous chromium(III) nitrate solutions, and coprecipitation from aqueous solutions containing both tin(IV) and chromium(III) ions. The freshly prepared gel catalyst materials comprise small (ca. 1-2 nm) particles of hydrous tin(IV) oxide, on the surface of which are sorbed chromate(VI) anions, {Cr(H 2 O) 6 3+ } cations, or polymeric γ-CrOOH depending on the preparative route. In all three cases, however, calcination at 573 K results in the formation of the mixed-valence chromium compound Cr 5 O 12 . At higher calcination temperatures Cr 2 O 3 is formed, which becomes more crystalline the higher the temperature. Concurrently, the size of the tin(IV) oxide particles increases, only slowly initially (ca. ×2 by 673 K and ca. ×4 by 873 K), but sintering to very large particles occurs at higher temperatures. No incorporation of chromium into the tin(IV) oxide lattice occurs even at high temperature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.